Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Announces Five Strategic Hires Across Equities and Equity Research

    The firm is expanding its Equities and Equity Research teams with several strategic hires, underscoring William Blair’s commitment to deepening expertise, broadening sector coverage, and delivering enhanced value to institutional clients.

    Read more

  • Viridian Therapeutics, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Viridian Therapeutics, Inc. (VRDN $31.45), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases.

    Read more

  • Advanced Specialty Care's Role in Reducing Healthcare Costs

    Advanced specialty care utilizes value-based models to reduce costs in cardiology, oncology, and kidney disease while enhancing outcomes.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures